Novo Nordisk has added ileus to the Postmarketing Experience section of the Wegovy label under Gastrointestinal Disorders. In October 2025, Severe Gastrointestinal Adverse Reactions was added to the WARNING AND PRECAUTIONS section of the label
Truthfully, this advice likely holds true no matter what method you're using to lose weight, but it's especially important with the effective weight loss drugs in the GLP-1 class
Enough dosing errors have been reported with compounded GLP-1 injectables (mis-calculated concentrations, wrong syringes, unit mix-ups) that in 2024, the FDA published a warning
The pathogenesis of ARDS primarily involves excessive inflammation and damage to the alveolar-capillary barrier, resulting in the accumulation of inflammatory cells, increased levels of pro-inflammatory factors and injury to alveolar epithelial cells
Are comfortable with compounded medications after understanding the distinction: If you have read the section above on compounded versus FDA-approved medications, discussed it with your primary care physician, and are comfortable proceeding with compounded formulations, this program may be appropriate
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide